Physician profile
Bugsu Ovunc
NPI 1891086088
$3,292.54
in general payments reported to CMS, 2019-2025
28 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 90% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.92 · 2020: $177 · 2021: $321 · 2022: $178 · 2023: $361 · 2024: $908 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,502 · Education: $89.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.77 |
| Education | $89.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $538.67 | 2020-2025 | |
| Amgen INC. | $488.05 | 2024-2025 | Tezspire |
| Astrazeneca Pharmaceuticals Lp | $438.20 | 2020-2025 | Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $350.33 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $301.76 | 2021-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $236.75 | 2019-2025 | |
| Genentech USA, INC. | $142.59 | 2021-2025 | Xolair |
| Blueprint Medicines Corporation | $124.04 | 2024-2025 | Ayvakit |
| Harmony Biosciences LLC | $89.51 | 2024-2025 | |
| Grifols USA, LLC | $82.42 | 2024-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $77.59 | 2020-2025 | Takhzyro |
| Azurity Pharmaceuticals, INC. | $49.18 | 2025 | Alvesco |
| Leo Pharma INC. | $41.29 | 2024 | Adbry |
| Electromed, INC. | $39.05 | 2025 | Smartvest |
| Covis Pharma Gmbh | $36.38 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $29.92 | 2024 | Opzelura |
| Lilly USA, LLC | $26.77 | 2025 | Ebglyss |
| Ventec Life Systems, INC. | $25.92 | 2020 | |
| Advanced Respiratory, INC | $25.88 | 2021 | |
| Csl Behring | $24.82 | 2020 | |
| Acadia Pharmaceuticals INC | $24.17 | 2023 | Daybue |
| Pharming Healthcare, INC. | $23.38 | 2025 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $20.57 | 2025 | Neffy |
| Phadia US INC. | $19.61 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $18.74 | 2020 | |
| Chiesi USA, INC. | $16.95 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bugsu Ovunc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.